SkinHealth Systems Inc. (SKIN)
Official siteCONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NASDAQ
Market Cap: $106.26M
Last updated: Nov 17, 2026 at 4:10 PM ET
SkinHealth Systems Inc. (SKIN) Statistics
SkinHealth Systems (SKIN) has a market cap of $106.26M and an enterprise value of $236.84M. Its net debt of $130.58M equals 122.89% of its market cap.
Total Valuation
Enterprise value is 122.89% above the market cap, as debt exceeds cash.
| Market Cap | $106.26M |
|---|---|
| Enterprise Value | $236.84M |
| Latest price (Nov 17, 2026) | $13.88 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.3x and 1.6x.
| P/S Ratio | 0.3x |
|---|---|
| Forward P/S | 0.4x |
| P/B Ratio | 1.6x |
| P/FCF Ratio | 4.0x |
| P/OCF Ratio | 4.5x |
Enterprise Valuation
Counting debt and cash, the company is valued at 7.0x EBITDA and 9.7x free cash flow.
| EV / Sales | 0.8x |
|---|---|
| EV / EBITDA | 7.0x |
| EV / EBIT | 36.9x |
| EV / FCF | 9.7x |
Price Statistics
The stock is down 45.80% over 52 weeks and trades 10.51% above its 50-day average.
| Beta (1Y) | 1.32 |
|---|---|
| 52-Week Change | -45.80% |
| 1-Month Change | +31.52% |
| 3-Month Change | +16.64% |
| 6-Month Change | +4.72% |
| 5-Year Change | -98.19% |
| Total Return (1Y) | -45.80% |
| Total Return (3Y CAGR) | -32.54% |
| Total Return (5Y CAGR) | -52.12% |
| Return vs SPY (1Y) | -58.60% |
| Max Drawdown (1Y) | -68.74% |
| Max Drawdown (3Y) | -89.03% |
| Sharpe Ratio (1Y) | -0.60 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $12.56 |
| 200-Day Average | $15.74 |
| 52-Week Range | $9.68 to $33.00 |
| RSI (14 Days) | 53.3 |
| Average Volume (20 Days) | 78.66K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.89x current liabilities, and total debt is 4.36x shareholder equity.
| Current Ratio | 2.89x |
|---|---|
| Quick Ratio | 2.22x |
| Debt / Equity | 4.36x |
| Debt / EBITDA | 7.68x |
| Debt / FCF | 10.71x |
| Interest Coverage | 0.25x |
Returns and Efficiency
Return on invested capital is 2.15% over the last 12 months, against a 5-year average of -2.40%.
| Return on Equity (ROE) | -32.81% |
|---|---|
| Return on Assets (ROA) | -4.70% |
| Return on Invested Capital (ROIC) | 2.15% |
| Return on Capital Employed (ROCE) | 2.01% |
| ROE (5Y Average) | -67.83% |
| ROA (5Y Average) | -8.72% |
| ROIC (5Y Average) | -2.40% |
| Asset Turnover | 0.65x |
| Inventory Turnover | 2.03x |
| Receivables Turnover | 15.98x |
| Cash Conversion Cycle | 142 days |
Scores
SKIN has an Altman Z-Score of -0.53, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.53 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $288.56M over the last 12 months is down 4.42% from the 12 months before.
| Revenue | $288.56M |
|---|---|
| Revenue Growth (YoY) | -4.42% |
| Gross Profit | $193.96M |
| Operating Income | $6.91M |
| Pretax Income | -$13.19M |
| Net Income | -$18.29M |
| EBITDA | $31.64M |
| EBIT | $6.41M |
| Reported EPS (TTM) | -$0.19 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 14.33% of the $389.06M in total assets.
| Cash and Equivalents | $112.39M |
|---|---|
| Total Debt | $242.96M |
| Net Debt | $130.58M |
| Net Debt Per Share | $20.06 |
| Working Capital | $131.75M |
| Shareholder Equity | $55.76M |
| Book Value Per Share | $8.56 |
| Tangible Book Value | -$97.98M |
| Total Assets | $389.06M |
| Total Liabilities | $333.31M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $883.00K of capital spending, operating cash flow left $22.69M of free cash flow.
| Operating Cash Flow | $23.58M |
|---|---|
| Capital Expenditures | $883.00K |
| Free Cash Flow | $22.69M |
| FCF Per Share | $3.48 |
| Depreciation and Amortization | $25.23M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 2.39%, against a 5-year average of -16.50%.
| Gross Margin | 67.22% |
|---|---|
| Operating Margin | 2.39% |
| Pretax Margin | -4.57% |
| Net Margin | -6.34% |
| EBITDA Margin | 10.97% |
| EBIT Margin | 2.22% |
| FCF Margin | 7.86% |
| Gross Margin (5Y Average) | 59.09% |
| Operating Margin (5Y Average) | -16.50% |
| Net Margin (5Y Average) | -34.11% |
Growth
Revenue fell 6.32% a year over 3 years, and EPS 7.17% a year.
| Revenue Growth (3Y CAGR) | -6.32% |
|---|---|
| Revenue Growth (5Y CAGR) | +20.36% |
| EPS Growth (3Y CAGR) | -7.17% |
| Book Value Per Share Growth (2Y CAGR) | +1.90% |
Dividends and Yields
SKIN does not pay a dividend. Its free cash flow yield is 25.12%.
| FCF Yield | 25.12% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-20 reverse split on Oct 14, 2026.
| Last Split Date | Oct 14, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 11 similar companies, SKIN has the 8th highest P/S.
P/S RatioPeer median 1.1x
ROICPeer median 2.47%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -1.95%
| P/S Ratio | 0.3x vs 1.1x median |
|---|---|
| ROIC | 2.15% vs 2.47% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -4.42% vs -1.95% median |
Analyst Forecast
Consensus estimates put revenue growth at -2.00% and EPS growth at 958.30% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -2.00% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +958.30% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About SKIN
What is SKIN's market cap?
SkinHealth Systems has a market cap of $106.26M. Its enterprise value, which adds debt and subtracts cash, is $236.84M.
How many shares of SKIN are outstanding?
SkinHealth Systems has 6.51M shares outstanding. The count is up 2.60% from a year earlier.
Does SKIN pay a dividend?
No. SkinHealth Systems does not pay a dividend.
How much debt does SKIN have?
SkinHealth Systems has $242.96M of total debt and $112.39M of cash and equivalents, a net debt position of $130.58M.
SKIN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors